FDA Commissioner Marty Makary said the agency may fast-track new drugs from pharmaceutical companies that “equalize” the cost of their medicines between the U.S. and other countries, Bloomberg’s ...

A Qatar-based study involving 121,700 patients has underscored the importance of the post-vaccination monitoring to optimise ...

Welcome to this week's Chutes & Ladders, our roundup of significant leadership hirings, firings and retirings across the ...

The selection of a first-line treatment for patients with advanced EGFR -positive non-small cell lung cancer (NSCLC) has ...

The deal gives AstraZeneca’s rare disease unit Alexion access to specialized capsids developed by the Japanese biotech JCR ...

AstraZeneca’s rare disease unit Alexion has penned a $825 million deal for adeno-associated virus (AAV) capsids from existing ...

The Lancet on the anti-IL-5 antibody mepolizumab in individuals with allergic asthma, evidence has accumulated that the pathogenetic role of eosinophils is fundamentally different between asthma ...

AstraZeneca AZN is one of the leading drugmakers in the oncology space. Oncology sales (comprising around 41% of ...

After several PD-1xVEGF competitors forged alliances with Big Pharma players, Summit Therapeutics, the frontrunner in this hot cancer drug field, is reportedly seeking its own deal. | After several PD ...

We view Pfizer’s dividends and share repurchase levels as reasonable. Pfizer has generally targeted close to a 50% payout in dividends as a percentage of normalized earnings, which seems about right ...

Rising one place to number one overall, the British drugmaker has overtaken the NHS as the preferred destination for science ...

Physicians treating patients with Crohn's disease face a plethora of drug choices. Yet, overall rates of clinical response seem stable over time,1 suggesting the existence of a therapeutic ceiling ...